Furthermore, the ORR of lorlatinib and crizotinib as a first-line therapeutic for advanced ALK+ NSCLC is 76% and 58%, revealing that lorlatinib has an advantage in regard to efficacy (22). The gene discussed is ALK; the disease is non-small cell lung carcinoma.